


# Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:


What is claimed is:

1. (Currently Amended) A compound of formula ~~formula~~ (I):




or a salt, solvate, or physiologically functional derivative thereof, wherein:


Ar<sup>1</sup> is a group selected from



(a)




(b)



(c)

and



(d)

wherein  $R^4$  represents hydrogen, halogen,  $-(CH_2)_qOR^7$ ,  $-NR^7C(O)R^8$ ,  $-NR^7SO_2R^8$ ,  $-SO_2NR^7R^8$ ,  $-NR^7R^8$ ,  $-OC(O)R^9$  or  $OC(O)NR^7R^8$ ,  
and  $R^3$  represents hydrogen, halogen or  $C_{1-4}$  alkyl;

or  $R^4$  represents  $-NHR^{10}$  and  $R^3$  and  $-NHR^{10}$  together form a 5- or 6-membered heterocyclic ring;

$R^5$  represents hydrogen, halogen,  $-OR^7$  or  $-NR^7R^8$ ;


$R^6$  represents hydrogen, halogen, halo $C_{1-4}$ alkyl,  $-OR^7$ ,  $-NR^7R^8$ ,  $-OC(O)R^9$  or  $OC(O)NR^7R^8$ ;

$R^7$  and  $R^8$  each independently represents hydrogen or  $C_{1-4}$  alkyl, or in the groups  $-NR^7R^8$ ,  $-SO_2NR^7R^8$  and  $-OC(O)NR^7R^8$ ,  $R^7$  and  $R^8$  independently represent hydrogen or  $C_{1-4}$  alkyl or together with the nitrogen atom to which they are attached form a 5-, 6- or 7- membered nitrogen-containing ring,

$R^9$  represents an aryl ~~(eg phenyl or naphthyl)~~ group which may be unsubstituted or substituted by one or more substituents selected from halogen,  $C_{1-4}$  alkyl, hydroxyl,  $C_{1-4}$  alkoxy or halo  $C_{1-4}$  alkyl; and

$q$  is zero or an integer from 1 to 4;

$Ar^2$  is a group:



wherein

$R^{11}$  is selected from hydrogen,  $C_{1-6}$ alkyl, hydroxy,  $C_{1-6}$ alkoxy, cyano, nitro, halo,  $C_{1-6}$ haloalkyl,  $XCO_2R^{16}$ ,  $-XC(O)NR^{15}R^{16}$ ,  $-XNR^{14}C(O)R^{15}$ ,  $-XNR^{14}C(O)NR^{15}R^{16}$ ,  $-XNR^{14}C(O)NC(O)NR^{15}R^{16}$ ,  $-XNR^{14}SO_2R^{15}$ ,  $-XSO_2NR^{17}R^{18}$ ,  $XSR^{14}$ ,  $XSOR^{14}$ ,  $XSO_2R^{14}$ ,  $-XNR^{15}R^{16}$ ,  $-XNR^{14}C(O)OR^{15}$ , or  $XNR^{14}SO_2NR^{15}R^{16}$ , or  $R^{11}$  is selected from  $-X$ -aryl,  $-X$ -hetaryl, or  $-X$ -(aryloxy), each optionally substituted by 1 or 2 groups independently selected from hydroxy,  $C_{1-6}$ alkoxy, halo,  $C_{1-6}$ alkyl,  $C_{1-6}$ haloalkyl, cyano, nitro,  $CONR^{15}R^{16}$ ,  $-NR^{14}C(O)R^{15}$ ,  $SR^{14}$ ,  $SOR^{14}$ ,  $-SO_2R^{14}$ ,  $-SO_2NR^{17}R^{18}$ ,  $-CO_2R^{16}$ ,  $-NR^{15}R^{16}$ , or hetaryl optionally substituted by 1 or 2 groups independently selected from hydroxy,  $C_{1-6}$ alkoxy, halo,  $C_{1-6}$ alkyl, or  $C_{1-6}$ haloalkyl;

X is  $-(CH_2)_r-$  or  $C_{2-6}$  alkenylene;

r is an integer from 0 to 6, preferably 0 to 4;

$R^{14}$  and  $R^{15}$  are independently selected from hydrogen,  $C_{1-6}$ alkyl,  $C_{3-7}$ cycloalkyl, aryl, hetaryl, hetaryl( $C_{1-6}$ alkyl)- and aryl( $C_{1-6}$ alkyl)- and  $R^{14}$  and  $R^{15}$  are each independently optionally substituted by 1 or 2 groups independently selected from halo,  $C_{1-6}$ alkyl,

$C_{3-7}$  cycloalkyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ haloalkyl,  $-NHC(O)(C_{1-6}alkyl)$ ,  $-SO_2(C_{1-6}alkyl)$ ,  $-SO_2(aryl)$ ,  $-CO_2H$ , and  $-CO_2(C_{1-4}alkyl)$ ,  $-NH_2$ ,  $-NH(C_{1-6}alkyl)$ , aryl( $C_{1-6}alkyl$ )-, aryl( $C_{2-6}alkenyl$ )-,

aryl( $C_{2-6}alkynyl$ )-, hetaryl( $C_{1-6}alkyl$ )-,  $-NHSO_2aryl$ ,  $-NH(hetarylC_{1-6}alkyl)$ ,  $-NHSO_2hetaryl$ ,

$-NHSO_2(C_{1-6}alkyl)$ ,  $-NHC(O)aryl$ , or  $-NHC(O)hetaryl$ :

or  $R^{14}$  and  $R^{15}$ , together with the nitrogen atom to which they are bonded, form a 5-, 6- or 7- membered nitrogen – containing ring;

or where  $R^{11}$  is  $-XNR^{14}C(O)NR^{15}R^{16}$ ,  $R^{14}$  and  $R^{15}$  may, together with the  $-NC(O)N-$  portion of the group  $R^1$  to which they are bonded, form a saturated or

unsaturated ring, ~~preferably a 5-, 6-, or 7-membered ring, for example an imidazolidine ring, such as imidazolidine-2,4-dione;~~

or where  $R^{11}$  is  $-XNR^{14}C(O)OR^{15}$ ,  $R^{14}$  and  $R^{15}$  may, together with the  $-NC(O)O-$  portion of the group  $R^{11}$  to which they are bonded, form a saturated or unsaturated ring, ~~preferably a 5-, 6-, or 7-membered ring, for example an oxazolidine ring, such as oxazolidine-2,4-dione;~~

$R^{16}$  is selected from hydrogen,  $C_{1-6}$ alkyl and  $C_{3-7}$  cycloalkyl;

or where  $R^{11}$  is  $-XC(O)NR^{15}R^{16}$  or  $-XNR^{14}C(O)NR^{15}R^{16}$ ,  $R^{15}$  and  $R^{16}$  may, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7-membered nitrogen containing ring;

$R^{17}$  and  $R^{18}$  are independently selected from hydrogen,  $C_{1-6}$ alkyl,  $C_{3-7}$ cycloalkyl, aryl, hetaryl, hetaryl( $C_{1-6}$ alkyl)- and aryl( $C_{1-6}$ alkyl)-, or  $R^{17}$  and  $R^{18}$ , together with the nitrogen to which they are bonded, form a 5-, 6-, or 7-membered nitrogen containing ring;

and  $R^{17}$  and  $R^{18}$  are each optionally substituted by one or two groups independently selected from halo,  $C_{1-6}$ alkyl, and  $C_{3-7}$ cycloalkyl,  $C_{1-6}$ haloalkyl;

$R^{12}$  is selected from hydrogen, pyridine,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, halo, aryl, aryl( $C_{1-6}$ alkyl)-,  $C_{1-6}$ haloalkoxy, and  $C_{1-6}$ haloalkyl;

$R^{13}$  is selected from hydrogen, hydroxy,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, halo, aryl, aryl( $C_{1-6}$ alkyl)-,  $C_{1-6}$ haloalkoxy, and  $C_{1-6}$ haloalkyl;

$R^1$  and  $R^2$  are independently selected from hydrogen and  $C_{1-4}$  alkyl with the proviso that the total number of carbon atoms in  $R^1$  and  $R^2$  is not more than 4;

one of  $R^{1a}$  and  $R^{2a}$  is selected from hydrogen and  $C_{1-4}$ alkyl, and the other of  $R^{1a}$  and  $R^{2a}$  represents hydrogen or  $C_{1-4}$ alkyl;

m is an integer of from 1 to 3;  
n is an integer of from 1 to 4; and  
p is zero or an integer of from 1 to 3;

and ---- represents a single or double bond.

2. (Currently Amended) A compound of formula (I) as defined in claim 1, or a salt, solvate or physiologically functional derivative thereof, wherein ~~except that:~~

R<sup>1a</sup> and R<sup>2a</sup> each represent hydrogen;

and in the group Ar<sup>1</sup>, either:

R<sup>4</sup> represents halogen, -(CH<sub>2</sub>)<sub>q</sub>OR<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>8</sup>, -NR<sup>7</sup>SO<sub>2</sub>R<sup>8</sup>, -SO<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>, -NR<sup>7</sup>R<sup>8</sup>,

-OC(O)R<sup>9</sup> or OC(O)NR<sup>7</sup>R<sup>8</sup>, and R<sup>3</sup> represents hydrogen or C<sub>1-4</sub> alkyl;

or:

R<sup>4</sup> represents -NHR<sup>10</sup> and R<sup>3</sup> and -NHR<sup>10</sup> together form a 5- or 6- membered heterocyclic ring;

3. (Currently Amended) A compound of formula (I) according to ~~either~~ claim 1 ~~or claim 2~~ wherein the group Ar<sup>1</sup> is selected from groups (a) and (b) as defined in claim 1.

4. (Currently Amended) A compound of formula (I) according to claim 1 ~~any of claims 1 to 3~~ wherein, in the group Ar<sup>2</sup>, R<sup>11</sup> is selected from hydrogen, C<sub>1-4</sub>alkyl, hydroxy, halo, -NR<sup>14</sup>C(O)NR<sup>15</sup>R<sup>16</sup>, -NR<sup>14</sup>SO<sub>2</sub>R<sup>15</sup> and XSO<sub>2</sub>NR<sup>17</sup>R<sup>18</sup> ~~wherein R<sup>14</sup> to R<sup>18</sup> are as defined in claim 1.~~

5. (Currently Amended) A compound of formula (I) according to claim 1 ~~any of claims 1 to 3~~ wherein, in the group Ar<sup>2</sup>, R<sup>11</sup> is selected from cyano, -CONR<sup>15</sup>R<sup>16</sup>, SR<sup>14</sup>, SOR<sup>14</sup> and SO<sub>2</sub>R<sup>14</sup>, ~~wherein R<sup>14</sup>, R<sup>15</sup> and R<sup>16</sup> are as defined in claim 1.~~

6. (Currently Amended) A compound of formula (I) according to claim 1 ~~any of claims 1 to 5~~ wherein R<sup>12</sup> and R<sup>13</sup> each represent hydrogen.

7. (Currently Amended) A compound of formula (I) according to claim 1 ~~any of claims 1 to 3~~ wherein R<sup>11</sup> represents hydrogen and R<sup>12</sup> and R<sup>13</sup> each represent halogen or C<sub>1-6</sub>alkyl.

8. (Currently Amended) A compound of formula (I) according to claim 1 ~~any of claims 1 to 7~~ wherein R<sup>1</sup> and R<sup>2</sup> are both hydrogen.

9. (Currently Amended) A compound of formula (I) according to claim 1 ~~any of claims 1 to 8~~ wherein each of m and n is independently 1 or 2, and p is zero or 1.

10. (Currently Amended) A compound of formula (I) according to claim 1 selected from:

4-((1R)-2-[[2-((3R)-3-[(2,6-Dichlorobenzyl)oxy]methyl)-2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;  
4-((1R)-2-[[2-((3R)-3-[(Benzyloxy)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;  
4-((1R)-2-[[2-((3S)-3-[(Benzyloxy)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;  
2-(Hydroxymethyl)-4-((1R)-1-hydroxy-2-[[2-((3R)-3-[(pyridine-3-ylmethoxy)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]amino]ethyl)phenol;  
4-((1R)-2-[[2-((3R)-3-[(6-Chloropyridin-3-yl)methoxy]methyl)-2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;  
4-((1R)-2-[[2-((3R)-3-[(2,6-Dichloropyridin-3-yl)methoxy]methyl)-2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;  
4-((1R)-2-[[2-2-[(Benzyloxy)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;  
4-((1R)-2-[[2-((3R)-3-[(5-Bromopyridin-3-yl)methoxy]methyl)-2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol;

3-[[[(2R)-7-[2-[(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)ethyl]-2,3-dihydro-1,4-benzodioxin-2-yl]methoxy)methyl]benzonitrile;

3-[[[(2R)-7-[2-[(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)ethyl]-2,3-dihydro-1,4-benzodioxin-2-yl]methoxy)methyl]benzamide;

4-[(1R)-2-[(2-[(3R)-3-[[3-(Cyclopentylthio)benzyl]oxy)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl]ethyl]amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;

4-[(1R)-2-[(2-[(3R)-3-[[3-(Cyclopentylsulfonyl)benzyl]oxy)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl]ethyl]amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;

2-(Hydroxymethyl)-4-[(1R)-1-hydroxy-2-[(2-[(3R)-3-[[5-[4-(methylsulfinyl)phenyl]pyridine-3-yl]methoxy)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl]ethyl]amino]ethyl]phenol;

N-{3-[[[(2R)-7-[2-[(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)ethyl]-2,3-dihydro-1,4-benzodioxin-2-yl]methoxy)methyl]phenyl}urea;

4-[(1R)-2-[(2-[(3R)-3-[[4-(Chlorobenzyl)oxy)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl]ethyl]amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;

4-[(1R)-2-[(2-[(3R)-3-[[4-(Fluorobenzyl)oxy)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl]ethyl]amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;

4-[(1R)-2-[(2-[(3R)-3-[[3,5-Dimethylbenzyl]oxy)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl]ethyl]amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;

2-(Hydroxymethyl)-4-[(1R)-1-hydroxy-2-[(2-[(3R)-3-[(1-phenylethoxy)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl]ethyl]amino]ethyl]phenol;

2-(Hydroxymethyl)-4-[(1R)-1-hydroxy-2-[(2-[(3R)-3-[[3-(methylsulfonyl)benzyl]oxy)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl]ethyl]amino)ethyl]phenol;

4-[(1R)-2-[(2-[(3R)-3-[[3-(2,6-Dichlorophenyl)propoxy)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl]ethyl]amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;

3-[[[(2R)-7-[2-[(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino)ethyl]-2,3-dihydro-1,4-benzodioxin-2-yl]methoxy)methyl]benzenesulfonamide;

6-{2-[(2-[(3*R*)-3-[(Benzyloxy)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]amino]-1-hydroxyethyl}-2-(hydroxymethyl)pyridine-3-ol;  
N-(5-{(1*R*)-2-[(2-[(3*R*)-3-[(Benzyloxy)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]amino]-1-hydroxyethyl}-2-hydroxyphenyl)methanesulfonamide;  
4-{(1*R*)-2-[(2-[(3*R*)-3-[(Benzyloxy)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]amino]-1-hydroxyethyl}-2-fluorophenol;  
4-{(1*R*)-2-[(2-[(3*R*)-3-[(Benzyloxy)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]amino]-1-hydroxyethyl}-3-methylphenol;  
(1*R*)-1-(4-Amino-3,5-dichlorophenyl)-2-[(2-[(3*R*)-3-[(benzyloxy)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]amino]ethanol;  
5-{(1*R*)-2-[(2-[(3*R*)-3-[(Benzyloxy)methyl]-2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]amino]-1-hydroxyethyl}-2-hydroxyphenylformamide;

or a salt, solvate or physiologically functional derivative thereof.

11. (Currently Amended) A method for the prophylaxis or treatment of a clinical condition in a mammal, ~~such as a human~~, for which a selective  $\beta_2$ -adrenoreceptor agonist is indicated, which comprises administering ~~administration of~~ a therapeutically effective amount of a compound of formula (I) according to claim 1 ~~any of claims 1 to 10~~, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.

12. (Canceled)


13. (Currently Amended) A pharmaceutical formulation comprising a compound of formula (I) according to claim 1 ~~any of claims 1 to 10~~, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.

14. (Canceled)




15. (Currently Amended) A process for the preparation of a compound of formula (I), according to claim 1 ~~any of claims 1 to 10~~, or a salt, solvate, or physiologically functional derivative thereof, which comprises:

(i) ~~deprotection of~~ deprotecting a protected intermediate, ~~for example of~~ formula (II)




or a salt or solvate thereof, wherein  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^{1a}$ ,  $\text{R}^{2a}$ ,  $m$ ,  $n$ ,  $p$  and  $\text{---}$  are as defined for the compound of formula (I),  $\text{Ar}^{1a}$  represents an optionally protected form of  $\text{Ar}^1$ ;  $\text{Ar}^{2a}$  represents an optionally protected form of  $\text{Ar}^2$  and  $\text{R}^{23}$  and  $\text{R}^{24}$  are each independently either hydrogen or a protecting group, provided that the compound of formula (II) contains at least one protecting group;

(ii) ~~alkylation of an amine of formula~~



wherein  ~~$\text{Ar}^{1a}$ ,  $\text{R}^{23}$  and  $\text{R}^{24}$  are as defined for formula (II) with a compound of formula (XV):~~



wherein  ~~$\text{---}$ ,  $\text{Ar}^2$ ,  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^{1a}$ ,  $\text{R}^{2a}$ ,  $m$ ,  $n$  and  $p$  are as defined for the compound of formula (II) and  $\text{L}$  is a leaving group as defined for formula (IX);~~

wherein said process is optionally followed by one or more of the following steps in any order selected from the group consisting of:

- (i) ~~optional removal of~~ removing any protecting groups;
- (ii) ~~optional separation of~~ separating an enantiomer from a mixture of enantiomers; and
- (iii) ~~optional conversion of~~ converting the product to a corresponding salt, solvate, or physiologically functional derivative thereof.

16. (New) A compound of formula (I) as defined in claim 1, or a salt, solvate or physiologically functional derivative thereof, wherein  $R^{11}$  is  $-XNR^{14}C(O)NR^{15}R^{16}$ , and wherein  $R^{14}$  and  $R^{15}$  form a 5-, 6-, or 7-membered ring.

17. (New) A compound of formula (I) as defined in claim 16, or a salt, solvate or physiologically functional derivative thereof, wherein the 5-, 6-, or 7-membered ring is an imidazolidine ring.

18. (New) A compound of formula (I) as defined in claim 17, or a salt, solvate or physiologically functional derivative thereof, wherein the imidazolidine ring is imidazolidine-2,4-dione.

19. (New) A compound of formula (I) as defined in claim 1, or a salt, solvate or physiologically functional derivative thereof, where  $R^{11}$  is  $-XNR^{14}C(O)OR^{15}$ , and wherein  $R^{14}$  and  $R^{15}$  form a 5-, 6-, or 7-membered ring.


20. (New) A compound of formula (I) as defined in claim 19, or a salt, solvate or physiologically functional derivative thereof, wherein the 5-, 6-, or 7-membered ring is an oxazolidine ring.

21. (New) A compound of formula (I) as defined in claim 20, or a salt, solvate or physiologically functional derivative thereof, wherein the oxazolidine ring is oxazolidine-2,4-dione.


22. (New) A method according to claim 11, wherein the mammal is a human.

23. (New) A process for the preparation of a compound of formula (I), according to claim 1, or a salt, solvate, or physiologically functional derivative thereof, which comprises:

alkylating an amine of formula



wherein  $\text{Ar}^{1a}$ ,  $\text{R}^{23}$  and  $\text{R}^{24}$  are as defined for formula (II) with a compound of formula (XV):



wherein  $\text{---}$ ,  $\text{Ar}^2$ ,  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^{1a}$ ,  $\text{R}^{2a}$ ,  $m$ ,  $n$  and  $p$  are as defined for the compound of formula (II) and  $\text{L}$  is a leaving group as defined for formula (IX);

wherein said process is optionally followed by one or more of the following steps in any order selected from the group consisting of:

- (i) removing any protecting groups;
- (ii) separating an enantiomer from a mixture of enantiomers; and
- (iii) converting the product to a corresponding salt, solvate, or physiologically functional derivative thereof.